CMS
57
2
WMT
68
-2
MAR
57
3
OI
23
3
PLD
35
5
CHD
34
7
SYK
50
4
IR
46
3
GT
43
2
DE
49
3
GRMN
53
3
SPG
45
2
NDAQ
46
2
SYF
78
7
MKC
54
3
ICE
53
5
HIG
48
5
EXR
42
5
V
70
14
SLG
37
6
CMS
57
2
WMT
68
-2
MAR
57
3
OI
23
3
PLD
35
5
CHD
34
7
SYK
50
4
IR
46
3
GT
43
2
DE
49
3
GRMN
53
3
SPG
45
2
NDAQ
46
2
SYF
78
7
MKC
54
3
ICE
53
5
HIG
48
5
EXR
42
5
V
70
14
SLG
37
6
Financhill
Back

Amicus Therapeutics Quote, Financials, Valuation and Earnings

The Trump Nuclear MEGA-Boom!

Here's why nuclear stocks are expected to skyrocket under Trump's second term.
Sell
44

FOLD
Amicus Therapeutics

Last Price:
$9.81
Seasonality Move:
5.47%

7 Day Trial

ALL ACCESS PASS

$ 7

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Amicus Therapeutics Price Quote

$9.81
+0.01 (+0.82%)
(Updated: December 21, 2024 at 5:26 AM ET)

Amicus Therapeutics Key Stats

Sell
44
Amicus Therapeutics (FOLD) is a Sell
Day range:
$9.60 - $9.88
52-week range:
$9.02 - $14.57
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.02
P/B ratio:
16.38%
Volume:
3.5M
Avg. volume:
2.6M
1-year change:
-23.68%
Market cap:
$2.9B
Revenue:
$399.4M
EPS:
$-0.34

How Much Does Amicus Therapeutics Make?

Data Unavailable

Is Amicus Therapeutics Growing As A Company?

Data Unavailable

Amicus Therapeutics Stock Price Performance

What Is Amicus Therapeutics 52-Week High & Low?

Amicus Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Amicus Therapeutics?

Data Unavailable

Is Amicus Therapeutics Cash Flow Positive?

Data Unavailable

Amicus Therapeutics Return On Invested Capital

Data Unavailable

Amicus Therapeutics Earnings Date & Stock Price

Amicus Therapeutics Competitors

  • Who Are Amicus Therapeutics's Competitors?
    Below is a list of companies who compete with Amicus Therapeutics or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Immuneering Corp (IMRX)
    • Insmed Inc (INSM)
    • Ionis Pharmaceuticals Inc (IONS)
    • Tonix Pharmaceuticals Holding Corp (TNXP)

Amicus Therapeutics Dividend Yield

Data Unavailable

Amicus Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 91.02%
Revenue: 36.73% 4.86%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable